TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Purchases $79,650.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) insider Sean Murphy acquired 15,000 shares of the business's stock in a transaction dated Monday, January 27th. The stock was purchased at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

TriSalus Life Sciences Stock Down 0.8 %

NASDAQ:TLSI traded down $0.04 during trading hours on Wednesday, reaching $4.93. 16,469 shares of the company's stock were exchanged, compared to its average volume of 23,643. The company has a market capitalization of $150.32 million, a P/E ratio of -1.98 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42. The business's 50-day simple moving average is $4.55 and its two-hundred day simple moving average is $4.75.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Roth Mkm reaffirmed a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price target on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Roth Capital raised TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday, November 11th. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a report on Friday, November 15th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of "Buy" and an average target price of $11.79.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds have recently modified their holdings of the stock. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at about $66,000. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at approximately $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $108,000. MSD Partners L.P. acquired a new position in TriSalus Life Sciences in the 3rd quarter worth approximately $184,000. Finally, Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after purchasing an additional 62,542 shares during the period. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.